SPY422.11-2.37 -0.56%
DIA340.76-2.65 -0.77%
IXIC14,039.68-33.17 -0.24%

Prelude Therapeutics Q1 Net Loss Narrows

05/11/2021 04:13

08:09 AM EDT, 05/11/2021 (MT Newswires) -- Prelude Therapeutics (PRLD) reported Tuesday a Q1 net loss of $0.47 per diluted share, compared with a loss of $5.12 a year ago. Analysts had expected a loss per share of $0.42.

The clinical-stage precision oncology company said cash and cash equivalents stood at $363 million as of March 31, compared with $218.3 million as of Dec. 31. Its cash and cash equivalents will be sufficient to fund operating expenses and capital expenditure requirements into 2023.

The company didn't report any revenue during the quarter.

Price: 40.70, Change: -0.91, Percent Change: -2.19